mRNA Display Reaches for the Clinic with New PCSK9 Inhibitor.

Published in: ACS medicinal chemistry letters (2022)

Merck & Co. recently reported one of the first mRNA display-derived clinical candidates in a bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Herein, we discuss the chemical and pharmacological challenges surmounted in bringing this compound to trials and the current outlook for mRNA display-based therapeutic development.

Keyphrases

low density lipoprotein
binding protein